Physician profile
Jadvinder Goraya
NPI 1518182344
$1,879.70
in general payments reported to CMS, 2019-2025
15 companies · $638 in 2025
The $638 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $47.30 · 2022: $69.65 · 2023: $419 · 2024: $706 · 2025: $638.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,757 · Education: $5.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,757.30 |
| Education | $5.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $416.50 | 2021-2025 | Breztri, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $380.17 | 2022-2025 | Trelegy Ellipta, Nucala, Shingrix |
| United Therapeutics Corporation | $189.30 | 2024-2025 | Tyvaso, Tyvaso |
| Boehringer Ingelheim Pharmaceuticals, INC. | $178.66 | 2022-2025 | Ofev |
| Amgen INC. | $150.40 | 2023-2024 | Tezspire |
| Genzyme Corporation | $96.28 | 2024-2025 | |
| Viatris Specialty LLC | $80.35 | 2025 | Yupelri |
| Mylan Specialty L.P. | $79.52 | 2024 | Yupelri |
| Paratek Pharmaceuticals, INC. | $73.66 | 2024-2025 | Nuzyra |
| Electromed, INC. | $61.18 | 2024 | Smartvest |
| Merck Sharp & Dohme LLC | $47.36 | 2024-2025 | Zerbaxa, Winrevair |
| Insmed, INC. | $35.72 | 2025 | Arikayce |
| Grifols USA, LLC | $33.64 | 2025 | Prolastin-C Liquid |
| Regeneron Healthcare Solutions, INC. | $28.73 | 2025 | Dupixent |
| Ani Pharmaceuticals, INC. | $28.23 | 2024 | Purified Cortrophin Gel |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jadvinder Goraya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.